

William P. Deni, Jr.
Charles H. Chevalier
J. Brugh Lower
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102
Tel: (973) 596-4500
Fax: (973) 596-0545

Attorneys for Plaintiffs

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

BAUSCH HEALTH COMPANIES INC.
f/k/a VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.; SALIX
PHARMACEUTICALS, INC.;
PROGENICS PHARMACEUTICALS, INC.;
and WYETH LLC f/k/a WYETH,

Plaintiffs,

v.

ACTAVIS LABORATORIES FL, INC.;
ACTAVIS LLC; TEVA PHARMACEUTICALS
USA, INC.; and TEVA PHARMACEUTICALS
INDUSTRIES LTD.,

Defendants.

Civil Action No. 19-13722

Document Electronically Filed

COMPLAINT FOR PATENT INFRINGEMENT

Plaintiffs Bausch Health Companies Inc. (“Bausch”), Salix Pharmaceuticals, Inc. (“Salix”), Progenics Pharmaceuticals, Inc. (“Progenics”), and Wyeth LLC (collectively, “Plaintiffs”) by way of Complaint against Defendants Actavis Laboratories FL, Inc. (“Actavis FL”), Actavis LLC, Teva Pharmaceuticals USA, Inc. (“Teva USA”), and Teva Pharmaceuticals Industries Ltd. (“Teva Ltd.”) (collectively, “Actavis” or “Defendants”), allege as follows:

THE PARTIES

1. Plaintiff Bausch is a corporation organized and existing under the laws of Canada. Its United States headquarters are located at 400 Somerset Corporate Blvd., Bridgewater, NJ 08807.

2. Plaintiff Salix is a corporation organized and existing under the laws of California, having its principal place of business at 8510 Colonnade Center Drive, Raleigh, NC 27615. Salix is the registered holder of approved New Drug Application No. 208271, which covers Relistor[®] tablets.

3. Plaintiff Progenics is a corporation organized and existing under the laws of Delaware, having its principal place of business at One World Trade Center, 47th Floor, New York, NY 10007.

4. Plaintiff Wyeth LLC, formerly Wyeth, is a Delaware LLC, having places of business at 235 East 42nd Street, New York, NY 10017, and One Giralda Farms, Madison, NJ 07940.

5. Upon information and belief, Defendant Actavis FL is a corporation organized and existing under the laws of Florida, having a place of business at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054.

6. Upon information and belief, Defendant Actavis LLC is a limited liability company organized and existing under the laws of Delaware, having its principal place of business at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, NJ 07054.

7. Upon information and belief, Defendant Teva USA is a corporation organized and existing under the laws of Delaware, having a place of business at 1090 Horsham Road, North Wales, PA 19454.

8. Upon information and belief, Defendant Teva Ltd., is a publicly-traded company organized and existing under the laws of Israel, having a place of business at 5 Basel Street, P.O. Box 3190, Petach Tikva 4951033, Israel.

9. Upon information and belief, Actavis FL and Actavis LLC are wholly-owned subsidiaries of Teva USA, which is a wholly-owned subsidiary of Teva Ltd.

NATURE OF THE ACTION

10. This is an action for infringement of United States Patent No. 10,307,417 (“the ’417 patent”) arising under the United States patent laws, Title 35, United States Code, § 100 et seq., including 35 U.S.C. §§ 271 and 281, and for declaratory judgment of infringement under 28 U.S.C. §§ 2201 and 2202. This action relates to Actavis’s filing of an Abbreviated New Drug Application (“ANDA”) under section 505(j) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to market its generic methylnaltrexone bromide tablets, 150 mg (“Actavis’s generic methylnaltrexone bromide tablets”).

JURISDICTION AND VENUE

11. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a), 2201 and 2202.

12. Upon information and belief, this Court has jurisdiction over Actavis FL. Upon information and belief, Actavis FL is in the business of manufacturing, marketing, importing and selling pharmaceutical products, including generic drug products. Upon information and belief, Actavis FL directly, or indirectly, manufactures, markets and sells generic drug products throughout the United States and in this judicial district, and this judicial district is a likely destination for Actavis’s generic methylnaltrexone bromide tablets. Upon information and belief,

Actavis FL has a place of business at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, New Jersey 07054. Upon information and belief, Actavis FL has previously submitted to the jurisdiction of this Court and has further previously availed itself of this Court by asserting counterclaims in other civil actions initiated in this jurisdiction.

13. Upon information and belief, this Court has jurisdiction over Actavis LLC. Upon information and belief, Actavis LLC is in the business of manufacturing, marketing, importing and selling pharmaceutical products, including generic drug products. Upon information and belief, Actavis LLC directly, or indirectly, manufactures, markets and sells generic drug products throughout the United States and in this judicial district, and this judicial district is a likely destination for Actavis's generic methylnaltrexone bromide tablets. Upon information and belief, Actavis LLC's principal place of business is at Morris Corporate Center III, 400 Interpace Parkway, Parsippany, New Jersey. Upon information and belief, Actavis LLC is registered in the State of New Jersey as a "wholesale[r]" of drugs, with Registration No. 5003899. Upon information and belief, Actavis LLC has previously submitted to the jurisdiction of this Court and has further previously availed itself of this Court by asserting counterclaims in other civil actions initiated in this jurisdiction.

14. Upon information and belief, this Court has jurisdiction over Teva USA. Upon information and belief, Teva USA is in the business of manufacturing, marketing, importing and selling pharmaceutical drug products, including generic drug products. Upon information and belief, Teva USA directly, or indirectly, manufactures, markets, imports and sells generic drugs throughout the United States and in this judicial district, and this judicial district is the likely destination for Actavis's generic methylnaltrexone bromide tablets. Upon information and belief, Teva USA operates and maintains branches in Fairfield, New Jersey; Woodcliff Lake, New Jersey;

and Parsippany, New Jersey. Upon information and belief, Teva USA is registered in the State of New Jersey as a “wholesale[r]” and “manufacturer and wholesale[r]” of drugs, with Registration Nos. 5003436 and 5000583. Upon information and belief Teva USA is registered to do business in New Jersey under New Jersey Entity ID No. 0100250184 and purposefully has conducted and continues to conduct business in this judicial district. Upon information and belief, Teva USA has previously submitted to the jurisdiction of this Court and has further previously availed itself of this Court by filing actions in this jurisdiction and asserting counterclaims in other civil actions initiated in this jurisdiction.

15. Upon information and belief, this Court has jurisdiction over Teva Ltd. Upon information and belief, Teva Ltd. is in the business of manufacturing, marketing, importing and selling pharmaceutical drug products, including generic drug products. Upon information and belief, Teva Ltd. intentionally markets and provides its generic pharmaceutical products to residents of this State, enjoys substantial income from this State, and maintains a physical presence within this State at least through its wholly-owned subsidiary Teva USA. Upon information and belief, Teva Ltd. has further previously availed itself of this Court by filing actions in this jurisdiction and asserting counterclaims in other civil actions initiated in this jurisdiction.

16. Upon information and belief, Defendants have a regular and established place of business in this judicial district because, for example, Actavis FL and Actavis LLC maintain places of business in this judicial district.

17. Upon information and belief, Actavis FL, Actavis LLC, Teva USA and Teva Ltd. hold themselves out as a unitary entity for purposes of manufacturing, marketing, selling and distributing generic products in the United States. Upon information and belief, Actavis FL, Actavis LLC, Teva USA and Teva Ltd. operate as a single integrated business.

18. Actavis's ANDA No. 209615 is the subject of an on-going infringement litigation in the District of New Jersey: *Bausch Health Companies Inc. et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 2:16-09038.

19. Teva USA and Teva Ltd. availed themselves of the rights, benefits and privileges of this Court by filing complaints in the District of New Jersey in at least the following actions: *Teva Pharmaceuticals USA, Inc. et al. v. Dr. Reddy's Laboratories, Ltd. et al.*, Civil Action No. 3:17-00517 (Teva USA and Teva Ltd.); *Teva Pharmaceuticals USA, Inc. et al. v. Sandoz, Inc. et al.*, Civil Action No. 3:17-00275 (Teva USA and Teva Ltd.); and *Teva Pharmaceutical USA, Inc. et al. v. Synthron Pharmaceuticals, Inc. et al.*, Civil Action No. 2:15-00472 (Teva USA and Teva Ltd.).

20. Actavis FL, Actavis LLC, Teva USA and/or Teva Ltd. consented to or did not contest the jurisdiction of this Court, for example, in at least the following District of New Jersey actions: *Valeant Pharmaceuticals Int'l, Inc. v. Actavis LLC*, Civil Action Nos. 2:16-00889, 2:15-08353 (Actavis LLC); *Rhodes Pharmaceuticals L.P. v. Actavis, Inc. et al.*, Civil Action No. 2:16-02667 (Actavis LLC); *Abraxis Bioscience, LLC et al. v. Actavis LLC*, Civil Action No. 2:16-01925 (Actavis LLC); *Sanofi-Aventis U.S. LLC et al. v. Actavis LLC et al.*, Civil Action No. 3:15-03107 (Actavis LLC); *Sumitomo Dainippon Pharma Co., Ltd. et al. v. Teva Pharmaceuticals USA, Inc. et al.*, Civil Action No. 2:15-06401 (Teva USA); *Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Teva Pharmaceuticals USA, Inc. et al.*, Civil Action No. 3:14-07811 (Teva USA and Teva Ltd.); *Novo Nordisk Inc. et al. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 3:14-04248 (Teva USA); *Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 1:14-06398 (Teva USA); *United Therapeutics et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 3:16-01816 (Actavis FL); *Sebel International Ltd. et al. v. Actavis Laboratories FL,*

Inc. et al., Case No. 2:17-04789 (Actavis FL, Teva USA and Teva Ltd.); *Bausch Health Companies Inc. et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 2:16-09038 (Actavis FL); and *Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. et al.*, Civil Action No. 2:15-06934 (Actavis FL).

21. Actavis FL, Actavis LLC, Teva USA and/or Teva Ltd. availed themselves of the rights, benefits and privileges of this Court by asserting counterclaims, for example, in at least the following prior District of New Jersey actions: *Rhodes Pharmaceuticals L.P. v. Actavis, Inc. et al.*, Civil Action No. 2:16-02667 (Actavis LLC); *Abraxis Bioscience, LLC et al. v. Actavis LLC*, Civil Action No. 2:16-01925 (Actavis LLC); *Valeant Pharmaceuticals Int'l, Inc. v. Actavis LLC*, Civil Action Nos. 2:16-00889, 2:15-08353 (Actavis LLC); *Novo Nordisk Inc. et al. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 3:14-04248 (Teva USA); *Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 1:14-06398 (Teva USA); *AstraZeneca Pharmaceuticals LP et al. v. Teva Pharmaceuticals USA, Inc. et al.*, Civil Action No. 3:07-03001 (Teva USA and Teva Ltd.); *United Therapeutics et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 3:16-01816 (Actavis FL); *Sebel International Ltd. et al. v. Actavis Laboratories FL, Inc. et al.*, Case No. 2:17-04789 (Actavis FL); *Bausch Health Companies Inc. et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 2:16-09038 (Actavis FL); and *Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. et al.*, Civil Action No. 2:15-06934 (Actavis FL).

22. Upon information and belief, venue is proper in this judicial district under 28 U.S.C. §§ 1391(c) and (d) and § 1400(b).

23. Actavis FL, Actavis LLC, Teva USA and/or Teva Ltd. did not contest venue in this judicial district in at least the following actions: *Valeant Pharmaceuticals Int'l, Inc. v. Actavis*

LLC, Civil Action Nos. 2:16-00889, 2:15-08353 (*Actavis LLC*); *Rhodes Pharmaceuticals L.P. v. Actavis, Inc. et al.*, Civil Action No. 2:16-02667 (*Actavis LLC*); *Abraxis Bioscience, LLC et al. v. Actavis LLC*, Civil Action No. 2:16-01925 (*Actavis LLC*); *Sanofi-Aventis U.S. LLC et al. v. Actavis LLC et al.*, Civil Action No. 3:15-03107 (*Actavis LLC*); *Sumitomo Dainippon Pharma Co., Ltd. et al. v. Teva Pharmaceuticals USA, Inc. et al.*, Civil Action No. 2:15-06401 (*Teva USA*); *Novo Nordisk Inc. et al. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 3:14-04248 (*Teva USA*); and *Boehringer Ingelheim Pharma GmbH & Co. KG et al. v. Teva Pharmaceuticals USA, Inc. et al.*, Civil Action No. 3:14-07811 (*Teva USA and Teva Ltd.*); *United Therapeutics et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 3:16-01816 (*Actavis FL*); *Sebela International Ltd. et al. v. Actavis Laboratories FL, Inc. et al.*, Case No. 2:17-04789 (*Actavis FL, Teva USA and Teva Ltd.*); *Bausch Health Companies Inc. et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 2:16-09038 (*Actavis FL*); and *Impax Laboratories, Inc. v. Actavis Laboratories FL, Inc. et al.*, Civil Action No. 2:15-06934 (*Actavis FL*).

24. Venue is proper against *Actavis FL*, *Actavis LLC*, and *Teva USA* because, *inter alia*, each maintains a regular and established place of business in this judicial district.

25. Venue is proper against *Teva Ltd.*, a foreign corporation, in any judicial district that has personal jurisdiction, including this district.

THE PATENT IN SUIT

26. The U.S. Patent and Trademark Office (“PTO”) issued the ’417 patent on June 4, 2019. The ’417 patent claims, *inter alia*, compositions of methylbuprenorphine. Plaintiffs hold all substantial rights in the ’417 patent and have the right to sue for infringement thereof. A copy of the ’417 patent is attached hereto as Exhibit A.

27. Salix is the holder of New Drug Application (“NDA”) No. 208271 for Relistor[®] tablets. In conjunction with NDA No. 208271, the ’417 patent is listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (“the Orange Book”), together with U.S. Patent Nos. 8,420,663, 8,524,276, 8,956,651, 9,180,125, 9,314,461, 9,492,445 and 9,724,343, which are the subject of an on-going infringement litigation in the District of New Jersey: *Bausch Health Companies Inc. et al. v. Actavis Laboratories FL, Inc.*, Civil Action No. 2:16-09038.

28. Methylnaltrexone bromide tablets, 150 mg, are sold in the United States under the trademark Relistor[®].

ACTAVIS’S INFRINGING ANDA SUBMISSION

29. Upon information and belief, Actavis filed or caused to be filed with the FDA ANDA No. 209615, under section 505(j) of the Act and 21 U.S.C. § 355(j).

30. Upon information and belief, Actavis’s ANDA No. 209615 seeks FDA approval to sell in the United States Actavis’s generic methylnaltrexone bromide tablets, intended to be a generic version of Relistor[®] 150 mg tablets.

31. The ’417 patent is listed in the Orange Book in conjunction with NDA No. 208271 for oral Relistor[®].

32. Upon information and belief, ANDA No. 209615 seeks approval of Actavis’s generic methylnaltrexone bromide tablets that are the same, or substantially the same, as Relistor[®] 150 mg tablets.

33. Upon information and belief, Actavis FL’s actions related to ANDA No. 209615 complained of herein were done with the cooperation, the participation, the assistance of, and at least in part for the benefit of Actavis LLC, Teva USA and Teva Ltd.

COUNT I AGAINST ACTAVIS

Infringement of the '417 Patent Under § 271(e)(2)

34. Paragraphs 1-33 are incorporated herein as set forth above.

35. Under 35 U.S.C. § 271(e)(2), Actavis has infringed at least one claim of the '417 patent by submitting, or causing to be submitted to the FDA, ANDA No. 209615 seeking approval for the commercial marketing of Actavis's generic methylnaltrexone bromide tablets before the expiration date of the '417 patent.

36. Upon information and belief, Actavis has chosen to seek approval for the commercial marketing of a formulation that infringes the '417 patent without any meritorious non-infringement or invalidity positions.

37. Upon information and belief, Actavis's generic methylnaltrexone bromide tablets will, if approved and marketed, infringe at least one claim of the '417 patent.

38. Upon information and belief, Actavis will, through the manufacture, use, import, offer for sale and/or sale of Actavis's generic methylnaltrexone tablets, directly infringe, contributorily infringe and/or induce infringement of at least one claim of the '417 patent.

39. If Actavis's marketing and sale of its generic methylnaltrexone tables prior to the expiration of the '417 patent is not enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no adequate remedy at law.

COUNT II AGAINST ACTAVIS

Declaratory Judgment of Infringement of the '417 Patent

40. Paragraphs 1-39 are incorporated herein as set forth above.

41. These claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

42. There is an actual case or controversy such that the Court may entertain Plaintiffs' request for declaratory relief consistent with Article III of the United States Constitution, and this actual case or controversy requires a declaration of rights by this Court.

43. Actavis has made, and will continue to make, substantial preparation in the United States to manufacture, use, offer to sell, sell and/or import Actavis's generic methylnaltrexone bromide tablets before the expiration date of the '417 patent, including Actavis's filing of ANDA No. 209615.

44. Upon information and belief, any commercial manufacture, use, offer for sale, sale and/or importation of Actavis's generic methylnaltrexone bromide tablets will directly infringe, contributorily infringe and/or induce infringement of at least one claim of the '417 patent.

45. Plaintiffs are entitled to declaratory judgment that future commercial manufacture, use, offer for sale, sale and/or importation of Actavis's generic methylnaltrexone bromide tablets will constitute infringement of at least one claim of the '417 patent.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs respectfully request that the Court enter judgment in their favor and against Actavis on the patent infringement claims set forth above and respectfully request that this Court:

1. Enter judgment that, under 35 U.S.C. § 271(e)(2), Actavis has infringed at least one claim of the '417 patent by submitting or causing to be submitted ANDA No. 209615 to the FDA to obtain approval for the commercial manufacture, use, import, offer for sale and/or sale in the United States of Actavis's generic methylnaltrexone bromide tablets before the expiration of the '417 patent;

2. Order that the effective date of any approval by the FDA of Actavis's generic methylnaltrexone bromide tablets be a date that is not earlier than the expiration of the '417 patent or such later date as the Court may determine;

3. Enjoin Actavis from the commercial manufacture, use, import, offer for sale and/or sale of Actavis's generic methylnaltrexone bromide tablets until expiration of the '417 patent or such later date as the Court may determine;

4. Enjoin Actavis and all persons acting in concert with Actavis from seeking, obtaining or maintaining approval of Actavis's ANDA No. 209615 until expiration of the '417 patent;

5. Declare this to be an exceptional case under 35 U.S.C. §§ 285 and 271(e)(4) and award Plaintiffs costs, expenses and disbursements in this action, including reasonable attorney's fees;

6. Award Plaintiffs such further and additional relief as this Court deems just and proper, including, but not limited to, any damages incurred by Plaintiffs in the event of a commercial launch of Actavis's generic methylnaltrexone bromide tablets before the expiration of the '417 patent, and relief for Actavis's willful infringement.

Dated: June 13, 2019
Newark, New Jersey

s/ William P. Deni, Jr. _____

William P. Deni, Jr.
Charles H. Chevalier
J. Brugh Lower
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102
Tel: (973) 596-4500
Fax: (973) 596-0545
wdeni@gibbonslaw.com
cchevalier@gibbonslaw.com
jlower@gibbonslaw.com

Attorneys for Plaintiffs

Of Counsel:

Bryan C. Diner
Justin J. Hasford
Kristi L. McIntyre (*pro hac vice* to be submitted)
Caitlin E. O'Connell (*pro hac vice* to be submitted)

**FINNEGAN, HENDERSON,
FARABOW, GARRETT & DUNNER, LLP**
901 New York Avenue, NW
Washington, DC 20001-4413
Tel: (202) 408-4000

Jessica M. Lebeis (*pro hac vice* to be submitted)
**FINNEGAN, HENDERSON,
FARABOW, GARRETT & DUNNER, LLP**
Two Seaport Lane
Boston, MA 02210-2001
Tel: (617) 646-1600

Attorneys for Plaintiffs
*Bausch Health Companies Inc.,
Salix Pharmaceuticals, Inc., and
Progenics Pharmaceuticals, Inc.*

CERTIFICATION OF NON-ARBITRABILITY
PURSUANT TO LOCAL CIVIL RULE 201.1(d)

Pursuant to Local Civil Rule 201.1(d), the undersigned counsel hereby certifies that this action seeks declaratory and injunctive relief and, therefore, is not subject to mandatory arbitration.

I certify under penalty of perjury that the foregoing is true and correct.

Dated: June 13, 2019
Newark, New Jersey

s/ William P. Deni, Jr. _____
William P. Deni, Jr.
GIBBONS P.C.
One Gateway Center
Newark, New Jersey 07102
Tel: (973) 596-4500
Fax: (973) 596-0545
wdeni@gibbonslaw.com

Attorneys for Plaintiffs